Logo image of STOK

STOKE THERAPEUTICS INC (STOK) Stock Fundamental Analysis

NASDAQ:STOK - Nasdaq - US86150R1077 - Common Stock - Currency: USD

8.33  -0.41 (-4.69%)

After market: 8.4 +0.07 (+0.84%)

Fundamental Rating

3

Overall STOK gets a fundamental rating of 3 out of 10. We evaluated STOK against 572 industry peers in the Biotechnology industry. While STOK seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, STOK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

STOK had negative earnings in the past year.
In the past year STOK has reported a negative cash flow from operations.
In the past 5 years STOK always reported negative net income.
In the past 5 years STOK always reported negative operating cash flow.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

STOK's Return On Assets of -35.95% is fine compared to the rest of the industry. STOK outperforms 60.75% of its industry peers.
Looking at the Return On Equity, with a value of -45.43%, STOK is in the better half of the industry, outperforming 68.38% of the companies in the same industry.
Industry RankSector Rank
ROA -35.95%
ROE -45.43%
ROIC N/A
ROA(3y)-40.41%
ROA(5y)-30.58%
ROE(3y)-53.24%
ROE(5y)-38.47%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

STOK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

More info and screens

6

2. Health

2.1 Basic Checks

STOK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, STOK has more shares outstanding
The number of shares outstanding for STOK has been increased compared to 5 years ago.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 1.60, we must say that STOK is in the distress zone and has some risk of bankruptcy.
STOK's Altman-Z score of 1.60 is fine compared to the rest of the industry. STOK outperforms 69.09% of its industry peers.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.6
ROIC/WACCN/A
WACC9.44%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 5.09 indicates that STOK has no problem at all paying its short term obligations.
STOK has a Current ratio (5.09) which is comparable to the rest of the industry.
STOK has a Quick Ratio of 5.09. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
STOK has a Quick ratio of 5.09. This is comparable to the rest of the industry: STOK outperforms 55.59% of its industry peers.
Industry RankSector Rank
Current Ratio 5.09
Quick Ratio 5.09
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

STOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.37%, which is quite good.
The Revenue has grown by 81.01% in the past year. This is a very strong growth!
EPS 1Y (TTM)13.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.16%
Revenue 1Y (TTM)81.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.94%

3.2 Future

Based on estimates for the next years, STOK will show a small growth in Earnings Per Share. The EPS will grow by 6.53% on average per year.
The Revenue is expected to grow by 62.40% on average over the next years. This is a very strong growth
EPS Next Y13.3%
EPS Next 2Y4.29%
EPS Next 3Y-4.63%
EPS Next 5Y6.53%
Revenue Next Year83.87%
Revenue Next 2Y45.5%
Revenue Next 3Y36.43%
Revenue Next 5Y62.4%

3.3 Evolution

STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STOK. In the last year negative earnings were reported.
Also next year STOK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as STOK's earnings are expected to decrease with -4.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.29%
EPS Next 3Y-4.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for STOK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STOKE THERAPEUTICS INC

NASDAQ:STOK (2/21/2025, 8:00:01 PM)

After market: 8.4 +0.07 (+0.84%)

8.33

-0.41 (-4.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)03-05 2025-03-05/amc
Inst Owners110.79%
Inst Owner Change-90.65%
Ins Owners4.7%
Ins Owner Change3.84%
Market Cap441.24M
Analysts83.75
Price Target22.29 (167.59%)
Short Float %17.81%
Short Ratio11.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.49%
Min EPS beat(2)13.51%
Max EPS beat(2)19.47%
EPS beat(4)4
Avg EPS beat(4)12%
Min EPS beat(4)6.63%
Max EPS beat(4)19.47%
EPS beat(8)7
Avg EPS beat(8)11.3%
EPS beat(12)9
Avg EPS beat(12)-14.71%
EPS beat(16)10
Avg EPS beat(16)-12.76%
Revenue beat(2)2
Avg Revenue beat(2)44.35%
Min Revenue beat(2)43.23%
Max Revenue beat(2)45.47%
Revenue beat(4)3
Avg Revenue beat(4)25.44%
Min Revenue beat(4)-15.51%
Max Revenue beat(4)45.47%
Revenue beat(8)6
Avg Revenue beat(8)5.23%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.86%
PT rev (3m)-6.99%
EPS NQ rev (1m)0.87%
EPS NQ rev (3m)2.98%
EPS NY rev (1m)1.02%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)16.67%
Revenue NQ rev (3m)26.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.35
P/FCF N/A
P/OCF N/A
P/B 1.9
P/tB 1.9
EV/EBITDA N/A
EPS(TTM)-2.1
EYN/A
EPS(NY)-2.17
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0.32
BVpS4.38
TBVpS4.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.95%
ROE -45.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.41%
ROA(5y)-30.58%
ROE(3y)-53.24%
ROE(5y)-38.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.05%
Cap/Sales 2.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.09
Quick Ratio 5.09
Altman-Z 1.6
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)148.22%
Cap/Depr(5y)185.41%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.16%
EPS Next Y13.3%
EPS Next 2Y4.29%
EPS Next 3Y-4.63%
EPS Next 5Y6.53%
Revenue 1Y (TTM)81.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.94%
Revenue Next Year83.87%
Revenue Next 2Y45.5%
Revenue Next 3Y36.43%
Revenue Next 5Y62.4%
EBIT growth 1Y-4.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.11%
EBIT Next 3Y-10.95%
EBIT Next 5Y10.98%
FCF growth 1Y-187.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-227.4%
OCF growth 3YN/A
OCF growth 5YN/A